<?xml version="1.0" encoding="UTF-8"?>
<ref id="ppat.1007395.ref037">
 <label>37</label>
 <mixed-citation publication-type="journal">
  <name>
   <surname>Gaudinski</surname>
   <given-names>MR</given-names>
  </name>, 
  <name>
   <surname>Coates</surname>
   <given-names>EE</given-names>
  </name>, 
  <name>
   <surname>Houser</surname>
   <given-names>K V</given-names>
  </name>, 
  <name>
   <surname>Chen</surname>
   <given-names>GL</given-names>
  </name>, 
  <name>
   <surname>Yamshchikov</surname>
   <given-names>G</given-names>
  </name>, 
  <name>
   <surname>Saunders</surname>
   <given-names>JG</given-names>
  </name>, 
  <etal>et al</etal>
  <source>Safety and pharmacokinetics of the Fc- modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults</source>. 
  <year>2018</year>; 
  <fpage>1</fpage>â€“
  <lpage>20</lpage>. 
  <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pmed.1002493" xmlns:xlink="http://www.w3.org/1999/xlink">10.1371/journal.pmed.1002493</ext-link>
  <?supplied-pmid 29364886?>
  <pub-id pub-id-type="pmid">29364886</pub-id>
 </mixed-citation>
</ref>
